Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep:339:116083.
doi: 10.1016/j.psychres.2024.116083. Epub 2024 Jul 10.

Cognitive reserve and cognition in mood disorders: A systematic review and meta-analysis

Patricia Camprodon-Boadas  1 , Michele De Prisco  2 , Francisco Diego Rabelo-da-Ponte  3 , Gisela Sugranyes  4 , Derek Clougher  5 , Inmaculada Baeza  6 , Carla Torrent  2 , Josefina Castro-Fornieles  6 , Yamila Tosetti  7 , Eduard Vieta  2 , Elena de la Serna  7 , Silvia Amoretti  8
Affiliations
Free article
Meta-Analysis

Cognitive reserve and cognition in mood disorders: A systematic review and meta-analysis

Patricia Camprodon-Boadas et al. Psychiatry Res. 2024 Sep.
Free article

Abstract

Cognitive functioning heterogeneity is a well-recognized phenomenon in individuals diagnosed with mood disorders. Cognitive Reserve (CR) has been linked to multiple positive outcomes, including cognitive performance in these patients. This systematic review and meta-analysis aim to provide a comprehensive analysis of the relationship between CR and cognitive functioning in individuals with mood disorders, including bipolar disorder and depressive disorders. Following PRISMA guidelines, a systematic review and meta-analysis was conducted of original research exploring the relationship between CR and cognitive performance in adult individuals with mood disorders. The literature search was conducted on PubMed, Scopus, and Web of Science, from 2002 to September 2023, and the Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of studies. Overall, 17 studies met the inclusion criteria for the systematic review and 11 for the meta-analysis. Both qualitative and quantitative findings suggested a positive relationship between CR measures and cognitive domains. CR emerges as a possible protective factor for cognitive functioning in adult individuals with mood disorders, potentially helping to mitigate the cognitive impairments associated with the disorder. These findings underscore the importance of the fact that promoting and enhancing CR could help in the cognitive prognosis of this population.

Keywords: Bipolar disorder; Cognitive dysfunction; Cognitive reserve; Major depressive disorder.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest SA has been a consultant to and/or has received honoraria/grants from Otsuka-Lundbeck, with no financial or other relationship relevant to the subject of this article. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, BoehringerIngelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, Janssen, Lundbeck, Medincell, Merck, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, SanofiAventis, Sunovion, Takeda, and Viatris, outside the submitted work. IB has received honoraria and travel support from Angelini and Lundbeck and grants from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III supported by ERDF Funds from the European Commission (PI18/0242/PI21/0391), National Drugs Plan, and Fundación Alicia Koplowitz. EV has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris, outside the submitted work. The rest of authors report no biomedical financial interests or potential conflicts of interest related to the present article.